Key statistics dashboard for TG Therapeutics, Inc. (TGTX). Valuation multiples (P/E, P/B, EV/EBITDA), profitability margins, financial-health ratios, per-share metrics and stock-level data in one consolidated view — the snapshot quantitative analysts and value investors check first.
Based in New York City and established in 1993, TG Therapeutics, Inc. is a biopharmaceutical company that has advanced to the commercial stage. Its core mission revolves around the acquisition, advancement, and marketing of novel therapeutic solutions. The company's focus areas specifically include B-cell related cancers (malignancies) and various autoimmune disorders.
Stock Data
| Price | $55.85 |
| Market Cap | $8.5B |
| Enterprise Value | $8.82B |
| Beta | 1.75 |
| Exchange | NASDAQ |
| Country | US |
Valuation Multiples
| P/E Ratio | 18.34 |
| Price / Book | 13.11 |
| P/S | 10.69 |
| EV/EBITDA | 65.75 |
| EV/Sales | 11.03 |
| EV/FCF | -15752.83 |
| P/FCF | -15267.35 |
| Earnings Yield | 5.58% |
| FCF Yield | -0.01% |
| Dividend Yield | 0.00% |
Profitability
| Gross Margin | 82.36% |
| EBIT Margin | 16.75% |
| EBITDA Margin | 16.78% |
| Operating Margin | 17.05% |
| Net Margin | 55.22% |
| Return on Equity | 72.30% |
| Return on Assets | 26.93% |
| Return on Invested Capital | 9.93% |
| Return on Capital Employed | 9.94% |
Financial Health
| Current Ratio | 4.27 |
| Quick Ratio | 3.72 |
| Cash Ratio | 1.80 |
| Debt / Equity | 1.25 |
| Debt / Assets | 46.01% |
| Net Debt / EBITDA | 2.03 |
| Interest Coverage | 3.64 |
Per-Share Data
| Revenue per share | 5.64 |
| Book Value per share | 4.26 |
| Cash per share | 3.90 |
| FCF per share | -0.00 |
| Tangible Book Value per share | 4.26 |
| Dividend per share | 0.00 |
Related companies: ACLX · ALKS · ARWR · CRSP · IMVT · KRYS · KYMR
Explore sector: Healthcare · Biotechnology
More sections of TGTX: Overview · Financials · Valuation · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks